XML 101 R28.htm IDEA: XBRL DOCUMENT
v3.25.1

Reportable segments | 12 Months Ended
--- | ---
Dec. 31, 2024
Disclosure of operating segments [abstract] |
Reportable segments | Reportable segments 22.1 Reportable segments (a)General information: The amount of each item presented in each operating segment is equal to that reported to the highest authority that makes decisions regarding the operation, in order to decide on the allocation of resources to the defined segments and to assess its performance. These operating segments mentioned are consistent with the way the Company is managed and how results will be reported by the Company. These segments reflect separate operating results that are regularly reviewed by the executive responsible for operational decisions in order to make decisions about the resources to be allocated to the segment and assess its performance (See Note 22.2). The performance of each segment is measured based on net income and revenues. Inter-segment sales are made using terms and conditions at current market rates. (b)Factors used to identify segments on which a report should be presented: The segments covered in the report are strategic business units that offer different products and services. These are managed separately because each business requires different technology and marketing strategies. (c)Description of the types of products and services from which each reportable segment obtains its income from ordinary activities The operating segments are as follows: (i)Specialty plant nutrients (ii)Iodine and its derivatives (iii)Lithium and its derivatives (iv)Industrial chemicals (v)Potassium (vi)Other products and services (d)Description of income sources for all the other segments Information regarding assets, liabilities, gains and expenses that cannot be assigned to the segments indicated above, due to the nature of production processes, is included under the "Unallocated amounts” category of the disclosed information. (e)Description of the nature of the differences between measurements of results of reportable segments and the result of the entity before the expense or income tax expense of incomes The information reported in the segments is extracted from the Company’s consolidated financial statements and therefore there is no need to prepare reconciliations between the data mentioned above and those reported in the respective segments, according to what is stated in paragraph 28 of IFRS 8, "Operating Segments". For the allocation of inventory valuation costs, we identify the direct expenses (can be directly allocated to products) and the common expenses (belong to co-production processes, for example common leaching expenses for production of Iodine and Nitrates), Direct costs are directly allocated to the product and the common costs are distributed according to percentages that consider different variables in their determination, such as margins, rotation of inventories, revenue, production etc. The allocation of other common costs that are not included in the inventory valuation process, but go straight to the cost of sales, use similar criteria: the costs associated with a product or sales in particular are assigned to that particular product or sales, and the common costs associated with different products or business lines are allocated according to the sales. (f)Description of the nature of the differences between measurements of assets of reportable segments and the Company´s assets Assets are not shown classified by segments, as this information is not readily available, some of these assets are not separable by the type of activity by which they are affected since this information is not used by management in decision-making with respect to resources to be allocated to each defined segment. All assets are disclosed in the "unallocated amounts" category. (g)Description of the nature of the differences between measurements of liabilities of reportable segments and the Company’s liabilities Liabilities are not shown classified by segments, as this information is not readily available, some of these liabilities are not separable by the type of activity by which they are affected, since this information is not used by management in decision-making regarding resources to be allocated to each defined segment. All liabilities are disclosed in the "unallocated amounts" category. 22.2 Reportable segment disclosures:
Operating segment items for the year ended December 31, 2024 |  | Specialty plant nutrients |  | Iodine and its derivatives |  | Lithium and its derivatives |  | Industrial chemicals |  | Potassium |  | Other products and services |  | Reportable segments |  | Operating segments |  | Unallocated amounts |  | Total as of December 31, 2024
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue |  | 941,940 |  |  | 968,312 |  |  | 2,241,250 |  |  | 78,155 |  |  | 270,783 |  |  | 28,321 |  |  | 4,528,761 |  |  | 4,528,761 |  |  | — |  |  | 4,528,761 |
Revenues from transactions with other operating segments of the same entity |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Revenues from external customers and transactions with other operating segments of the same entity |  | 941,940 |  |  | 968,312 |  |  | 2,241,250 |  |  | 78,155 |  |  | 270,783 |  |  | 28,321 |  |  | 4,528,761 |  |  | 4,528,761 |  |  | — |  |  | 4,528,761 |
Costs of sales |  | (775,152) |  |  | (444,904) |  |  | (1,666,328) |  |  | (47,453) |  |  | (236,390) |  |  | (31,427) |  |  | (3,201,654) |  |  | (3,201,654) |  |  | — |  |  | (3,201,654) |
Administrative expenses |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (185,959) |  |  | (185,959) |
Finance expense |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (197,544) |  |  | (197,544) |
Depreciation and amortization expense |  | (72,211) |  |  | (57,038) |  |  | (187,538) |  |  | (6,328) |  |  | (19,275) |  |  | (34) |  |  | (342,424) |  |  | (342,424) |  |  | — |  |  | (342,424) |
The entity’s interest in the income of associates and joint ventures accounted for by the equity method |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 11,025 |  |  | 11,025 |
Income before taxes |  | 166,788 |  |  | 523,408 |  |  | 574,922 |  |  | 30,702 |  |  | 34,393 |  |  | (3,106) |  |  | 1,327,107 |  |  | 1,327,107 |  |  | (352,693) |  |  | 974,414 |
Income tax expense |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (282,573) |  |  | (282,573) |
Net income (loss) |  | 166,788 |  |  | 523,408 |  |  | 574,922 |  |  | 30,702 |  |  | 34,393 |  |  | (3,106) |  |  | 1,327,107 |  |  | 1,327,107 |  |  | (635,266) |  |  | 691,841 |
Assets |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 11,495,569 |  |  | 11,495,569 |
Equity-accounted investees |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 585,794 |  |  | 585,794 |
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,181,113) |  |  | (1,181,113) |
Liabilities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 6,297,502 |  |  | 6,297,502 |
Impairment loss of financial assets recognized in income |  |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | — |  |  | (639) |  |  | (639) |
Impairment loss of non-financial assets recognized in income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (7,134) |  |  | (7,134) |
Cash flows |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash flows from operating activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,274,678 |  |  | 1,274,678 |
Cash flows used in investing activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,213,992) |  |  | (1,213,992) |
Cash flows from financing activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 282,383 |  |  | 282,383 |
Operating segment items for the year ended December 31, 2023 |  | Specialty plant nutrients |  | Iodine and its derivatives |  | Lithium and its derivatives |  | Industrial chemicals |  | Potassium |  | Other products and services |  | Reportable segments |  | Operating segments |  | Unallocated amounts |  | Total as of December 31, 2023
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue |  | 913,912 |  |  | 892,151 |  |  | 5,180,114 |  |  | 175,223 |  |  | 279,050 |  |  | 27,040 |  |  | 7,467,490 |  |  | 7,467,490 |  |  | — |  |  | 7,467,490 |
Revenues from transactions with other operating segments of the same entity |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Revenues from external customers and transactions with other operating segments of the same entity |  | 913,912 |  |  | 892,151 |  |  | 5,180,114 |  |  | 175,223 |  |  | 279,050 |  |  | 27,040 |  |  | 7,467,490 |  |  | 7,467,490 |  |  | — |  |  | 7,467,490 |
Costs of sales |  | (691,509) |  |  | (355,717) |  |  | (2,955,669) |  |  | (141,351) |  |  | (219,597) |  |  | (28,593) |  |  | (4,392,436) |  |  | (4,392,436) |  |  | — |  |  | (4,392,436) |
Administrative expenses |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (175,765) |  |  | (175,765) |
Finance expense |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (138,402) |  |  | (138,402) |
Depreciation and amortization expense |  | (70,342) |  |  | (53,140) |  |  | (124,010) |  |  | (15,232) |  |  | (18,006) |  |  | (57) |  |  | (280,787) |  |  | (280,787) |  |  | — |  |  | (280,787) |
The entity’s interest in the income of associates and joint ventures accounted for by the equity method |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 593 |  |  | 593 |
Income before taxes |  | 222,403 |  |  | 536,434 |  |  | 2,224,445 |  |  | 33,872 |  |  | 59,453 |  |  | (1,553) |  |  | 3,075,054 |  |  | 3,075,054 |  |  | (268,036) |  |  | 2,807,018 |
Income tax expense |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,876,751) |  |  | (1,876,751) |
Net income (loss) |  | 222,403 |  |  | 536,434 |  |  | 2,224,445 |  |  | 33,872 |  |  | 59,453 |  |  | (1,553) |  |  | 3,075,054 |  |  | 3,075,054 |  |  | (2,144,787) |  |  | 930,267 |
Assets |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 10,778,837 |  |  | 10,778,837 |
Equity-accounted investees |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 86,417 |  |  | 86,417 |
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,785,385 |  |  | 2,785,385 |
Liabilities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 6,301,408 |  |  | 6,301,408 |
Impairment loss of financial assets recognized in income |  |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | — |  |  | 202 |  |  | 202 |
Impairment loss of non-financial assets recognized in income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (47,068) |  |  | (47,068) |
Cash flows |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash flows from operating activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (196,639) |  |  | (196,639) |
Cash flows used in investing activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,481,493) |  |  | (1,481,493) |
Cash flows from financing activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 66,261 |  |  | 66,261 |
Operating segment items for the year ended December 31, 2022 |  | Specialty plant nutrients |  | Iodine and its derivatives |  | Lithium and its derivatives |  | Industrial chemicals |  | Potassium |  | Other products and services |  | Reportable segments |  | Operating segments |  | Unallocated amounts |  | Total as of December 31, 2022
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue |  | 1,172,334 |  |  | 754,339 |  |  | 8,152,939 |  |  | 165,200 |  |  | 437,180 |  |  | 28,586 |  |  | 10,710,578 |  |  | 10,710,578 |  |  | — |  |  | 10,710,578 |
Revenues from transactions with other operating segments of the same entity |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Revenues from external customers and transactions with other operating segments of the same entity |  | 1,172,334 |  |  | 754,339 |  |  | 8,152,939 |  |  | 165,200 |  |  | 437,180 |  |  | 28,586 |  |  | 10,710,578 |  |  | 10,710,578 |  |  | — |  |  | 10,710,578 |
Costs of sales |  | (722,261) |  |  | (282,100) |  |  | (3,636,852) |  |  | (112,247) |  |  | (193,581) |  |  | (26,912) |  |  | (4,973,953) |  |  | (4,973,953) |  |  | — |  |  | (4,973,953) |
Administrative expenses |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (142,644) |  |  | (142,644) |
Finance expense |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (86,651) |  |  | (86,651) |
Depreciation and amortization expense |  | (63,321) |  |  | (53,734) |  |  | (88,510) |  |  | (14,724) |  |  | (24,043) |  |  | (126) |  |  | (244,458) |  |  | (244,458) |  |  | — |  |  | (244,458) |
The entity’s interest in the income of associates and joint ventures accounted for by the equity method |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 20,159 |  |  | 20,159 |
Income before taxes |  | 450,073 |  |  | 472,239 |  |  | 4,516,087 |  |  | 52,953 |  |  | 243,599 |  |  | 1,674 |  |  | 5,736,625 |  |  | 5,736,625 |  |  | (250,129) |  |  | 5,486,496 |
Income tax expense |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,572,212) |  |  | (1,572,212) |
Net income (loss) |  | 450,073 |  |  | 472,239 |  |  | 4,516,087 |  |  | 52,953 |  |  | 243,599 |  |  | 1,674 |  |  | 5,736,625 |  |  | 5,736,625 |  |  | (1,822,341) |  |  | 3,914,284 |
Assets |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 10,819,101 |  |  | 10,819,101 |
Equity-accounted investees |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 54,386 |  |  | 54,386 |
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,757,581 |  |  | 1,757,581 |
Other Liabilities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 5,887,100 |  |  | 5,887,100 |
Impairment loss of financial assets recognized in income |  |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | — |  |  | 3,369 |  |  | 3,369 |
Impairment loss of non-financial assets recognized in income |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (42,233) |  |  | (42,233) |
Cash flows |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash flows from operating activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,077,595 |  |  | 4,077,595 |
Cash flows used in investing activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (909,401) |  |  | (909,401) |
Cash flows from financing activities |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (2,002,969) |  |  | (2,002,969) |
22.3 Statement of comprehensive income classified by reportable segments based on groups of products
Items in the statement of comprehensive income for the year ended December 31,2024 |  | Specialty plant nutrients |  | Iodine and its derivatives |  | Lithium and its derivatives |  | Industrial chemicals |  | Potassium |  | Other products and services |  | Corporate Unit |  | Total segments and Corporate unit
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue |  | 941,940 |  | 968,312 |  | 2,241,250 |  | 78,155 |  | 270,783 |  | 28,321 |  | — |  | 4,528,761
Costs of sales |  | (775,152) |  |  | (444,904) |  |  | (1,666,328) |  |  | (47,453) |  |  | (236,390) |  |  | (31,427) |  |  | — |  | (3,201,654) |
Gross profit |  | 166,788 |  | 523,408 |  | 574,922 |  | 30,702 |  | 34,393 |  | (3,106) |  | — |  | 1,327,107
Other incomes by function |  | — |  | — |  | — |  | — |  | — |  | — |  | 32,229 |  | 32,229
Administrative expenses |  | — |  | — |  | — |  | — |  | — |  | — |  | (185,959) |  |  | (185,959) |
Other expenses by function |  | — |  | — |  | — |  | — |  | — |  | — |  | (104,698) |  |  | (104,698) |
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 |  | — |  | — |  | — |  | — |  | — |  | — |  | (639) |  | (639)
Other losses |  | — |  | — |  | — |  | — |  | — |  | — |  | (2,142) |  | (2,142)
Financial income |  | — |  | — |  | — |  | — |  | — |  | — |  | 103,642 |  | 103,642
Financial costs |  | — |  | — |  | — |  | — |  | — |  | — |  | (197,544) |  |  | (197,544) |
Interest in the income of associates and joint ventures accounted for by the equity method |  | — |  | — |  | — |  | — |  | — |  | — |  | 11,025 |  | 11,025
Exchange differences |  | — |  | — |  | — |  | — |  | — |  | — |  | (8,607) |  |  | (8,607) |
Income before taxes |  | 166,788 |  | 523,408 |  | 574,922 |  | 30,702 |  | 34,393 |  | (3,106) |  | (352,693) |  |  | 974,414
Income tax expense |  | — |  | — |  | — |  | — |  | — |  | — |  | (282,573) |  |  | (282,573) |
Net income |  | 166,788 |  | 523,408 |  | 574,922 |  | 30,702 |  | 34,393 |  | (3,106) |  | (635,266) |  |  | 691,841
Items in the statement of comprehensive income for the year ended December 31,2023 |  | Specialty plant nutrients |  | Iodine and its derivatives |  | Lithium and its derivatives |  | Industrial chemicals |  | Potassium |  | Other products and services |  | Corporate Unit |  | Total segments and Corporate unit
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue |  | 913,912 |  | 892,151 |  | 5,180,114 |  | 175,223 |  | 279,050 |  | 27,040 |  | — |  | 7,467,490
Costs of sales |  | (691,509) |  |  | (355,717) |  |  | (2,955,669) |  |  | (141,351) |  |  | (219,597) |  |  | (28,593) |  |  | — |  | (4,392,436) |
Gross profit |  | 222,403 |  | 536,434 |  | 2,224,445 |  | 33,872 |  | 59,453 |  | (1,553) |  | — |  | 3,075,054
Other incomes by function |  | — |  | — |  | — |  | — |  | — |  | — |  | 40,557 |  | 40,557
Administrative expenses |  | — |  | — |  | — |  | — |  | — |  | — |  | (175,765) |  |  | (175,765) |
Other expenses by function |  | — |  | — |  | — |  | — |  | — |  | — |  | (93,400) |  |  | (93,400) |
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 |  | — |  | — |  | — |  | — |  | — |  | — |  | 202 |  |  | 202 |
Other gains |  | — |  | — |  | — |  | — |  | — |  | — |  | (2,254) |  |  | (2,254) |
Financial income |  | — |  | — |  | — |  | — |  | — |  | — |  | 122,726 |  | 122,726
Financial costs |  | — |  | — |  | — |  | — |  | — |  | — |  | (138,402) |  |  | (138,402) |
Interest in the income of associates and joint ventures accounted for by the equity method |  | — |  | — |  | — |  | — |  | — |  | — |  | 593 |  | 593
Exchange differences |  | — |  | — |  | — |  | — |  | — |  | — |  | (22,293) |  |  | (22,293) |
Income before taxes |  | 222,403 |  | 536,434 |  | 2,224,445 |  | 33,872 |  | 59,453 |  | (1,553) |  | (268,036) |  |  | 2,807,018
Income tax expense |  | — |  | — |  | — |  | — |  | — |  | — |  | (1,876,751) |  |  | (1,876,751) |
Net income |  | 222,403 |  | 536,434 |  | 2,224,445 |  | 33,872 |  | 59,453 |  | (1,553) |  | (2,144,787) |  |  | 930,267
Items in the statement of comprehensive income for the year ended December 31,2022 |  | Specialty plant nutrients |  | Iodine and its derivatives |  | Lithium and its derivatives |  | Industrial chemicals |  | Potassium |  | Other products and services |  | Corporate Unit |  | Total segments and Corporate unit
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue |  | 1,172,334 |  | 754,339 |  | 8,152,939 |  | 165,200 |  | 437,180 |  | 28,586 |  | — |  | 10,710,578
Cost of sales |  | (722,261) |  |  | (282,100) |  |  | (3,636,852) |  |  | (112,247) |  |  | (193,581) |  |  | (26,912) |  |  | — |  | (4,973,953) |
Gross profit |  | 450,073 |  | 472,239 |  | 4,516,087 |  | 52,953 |  | 243,599 |  | 1,674 |  | — |  | 5,736,625
Other incomes by function |  | — |  | — |  | — |  | — |  | — |  | — |  | 9,854 |  | 9,854
Administrative expenses |  | — |  | — |  | — |  | — |  | — |  | — |  | (142,644) |  |  | (142,644) |
Other expenses by function |  | — |  | — |  | — |  | — |  | — |  | — |  | (75,971) |  |  | (75,971) |
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 |  | — |  | — |  | — |  | — |  | — |  | — |  | 3,369 |  | 3,369
Other losses |  | — |  | — |  | — |  | — |  | — |  | — |  | 117 |  |  | 117 |
Financial income |  | — |  | — |  | — |  | — |  | — |  | — |  | 47,038 |  | 47,038
Financial costs |  | — |  | — |  | — |  | — |  | — |  | — |  | (86,651) |  |  | (86,651) |
Interest in the income of associates and joint ventures accounted for by the equity method |  | — |  | — |  | — |  | — |  | — |  | — |  | 20,159 |  | 20,159
Exchange differences |  | — |  | — |  | — |  | — |  | — |  | — |  | (25,400) |  |  | (25,400) |
Income before taxes |  | 450,073 |  | 472,239 |  | 4,516,087 |  | 52,953 |  | 243,599 |  | 1,674 |  | (250,129) |  |  | 5,486,496
Income tax expense |  | — |  | — |  | — |  | — |  | — |  | — |  | (1,572,212) |  |  | (1,572,212) |
Net income from continuing operations |  | 450,073 |  | 472,239 |  | 4,516,087 |  | 52,953 |  | 243,599 |  | 1,674 |  | (1,822,341) |  |  | 3,914,284
22.4 Disclosures on geographical areas As indicated in paragraph 33 of IFRS 8, the entity discloses geographical information on its revenue from operating activities with external customers and from non-current assets that are not financial instruments, deferred income tax assets, assets related to post-employment benefits or rights derived from insurance contracts. 22.5 Disclosures on main customers With respect to the degree of dependency of the Company on its customers, in accordance with paragraph 34 of IFRS 8, the Company has no external customers who individually represent 10% or more of its revenue. 22.6 Segments by geographical areas
Segments by geographical areas |  | Chile |  | Latin America and the Caribbean |  | Europe |  | North America |  | Asia and others |  | Total
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue at December 31, 2024 |  | 171,551 |  |  | 240,629 |  |  | 681,607 |  |  | 689,794 |  |  | 2,745,180 |  |  | 4,528,761 |
Non-current assets at December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Investment accounted for under the equity method |  | — |  |  | — |  |  | 13,912 |  |  | 17,470 |  |  | 554,412 |  |  | 585,794 |
Intangible assets other than goodwill |  | 73,762 |  |  | 450 |  |  | 6,466 |  |  | 547 |  |  | 86,743 |  |  | 167,968 |
Goodwill |  | — |  |  | 86 |  |  | 138 |  |  | 724 |  |  | — |  |  | 948 |
Property, plant and equipment, net |  | 3,465,971 |  |  | 6,651 |  |  | 10,598 |  |  | 8,277 |  |  | 942,148 |  |  | 4,433,645 |
Right-of-use assets |  | 46,122 |  |  | 1,806 |  |  | 3,234 |  |  | 6,112 |  |  | 26,796 |  |  | 84,070 |
Other non-current assets |  | 68,777 |  |  | 29 |  |  | — |  |  | 5,413 |  |  | 289,947 |  |  | 364,166 |
Non-current assets |  | 3,654,632 |  |  | 9,022 |  |  | 34,348 |  |  | 38,543 |  |  | 1,900,046 |  |  | 5,636,591 |
Segments by geographical areas |  | Chile |  | Latin America and the Caribbean |  | Europe |  | North America |  | Asia and others |  | Total
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue for the year ended December 31, 2023 |  | 169,681 |  | 210,299 |  | 828,112 |  | 783,611 |  | 5,475,787 |  | 7,467,490
Non-current assets at December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Investment accounted for under the equity method |  | — |  | 22,490 |  | 42,726 |  | 17,657 |  | 3,544 |  | 86,417
Intangible assets other than goodwill |  | 67,671 |  | 360 |  | 6,440 |  | 876 |  | 80,527 |  | 155,874
Goodwill |  | — |  | 86 |  | 148 |  | 724 |  | — |  | 958
Property, plant and equipment, net |  | 2,888,778 |  | 776 |  | 14,485 |  | 6,322 |  | 699,576 |  | 3,609,937
Right-of-use assets |  | 32,359 |  | 19 |  | 3,716 |  | 8,619 |  | 28,480 |  | 73,193
Other non-current assets |  | 60,363 |  | 18 |  | — |  | 5,099 |  | 308,220 |  | 373,700
Non-current assets |  | 3,049,171 |  | 23,749 |  | 67,515 |  | 39,297 |  | 1,120,347 |  | 4,300,079
Segments by geographical areas |  | Chile |  | Latin America and the Caribbean |  | Europe |  | North America |  | Asia and others |  | Total
|  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$ |  | ThUS$
Revenue for the year ended December 31, 2022 |  | 223,148 |  | 339,940 |  | 932,558 |  | 914,187 |  | 8,300,745 |  | 10,710,578
Non-current assets at December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Investment accounted for under the equity method |  | — |  | 20,792 |  | 15,939 |  | 17,655 |  | — |  | 54,386
Intangible assets other than goodwill |  | 75,666 |  | 428 |  | 6,497 |  | 1,345 |  | 82,400 |  | 166,336
Goodwill |  | — |  | 86 |  | 158 |  | 723 |  | — |  | 967
Property, plant and equipment, net |  | 2,269,923 |  | 743 |  | 14,978 |  | 4,506 |  | 436,688 |  | 2,726,838
Right-of-use assets |  | 32,312 |  | 47 |  | 1,651 |  | 2,739 |  | 24,118 |  | 60,867
Other non-current assets |  | 46,640 |  | 17 |  | 6 |  | 4,706 |  | 1,027 |  | 52,396
Non-current assets |  | 2,424,541 |  | 22,113 |  | 39,229 |  | 31,674 |  | 544,233 |  | 3,061,790

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Entitys Reportable Segments Explanatory [Text Block] + References No definition available. + Details
Name: | sqm_DisclosureOfEntitysReportableSegmentsExplanatoryTextBlock
Namespace Prefix: | sqm_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration